![](/img/cover-not-exists.png)
341TiPPhase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE
Licitra, L., Even, C., Haddad, R., Tahara, M., Goswami, T., Franks, A., Emeribe, U., Jarkowski, A., Melillo, G., Ferris, R.L.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv527.28
Date:
December, 2015
File:
PDF, 36 KB
english, 2015